To understand the relevance of on-treatment CMV titers to ICI-hepatitis, we used a second cohort of 49 patients and analyzed serum anti-CMV IgG and IgM at three different time points (before, 6 weeks, and 12 weeks after ICI initiation; Fig. 2; cohort 2)). This evidence concerns the gene CD40LG and hepatitis A virus infection.